Jinan Hongyuan Chemical Co.,Ltd

Jinan Hongyuan Chemical Co.,Ltd

info@hychem-china.com

86-13954187575

Jinan Hongyuan Chemical Co.,Ltd
Casa> Blog
June 08, 2021
According to the analysis of CDE drug review, 30 category 1 therapeutic biological products and 46 category 1 chemical drugs were accepted, Geli, Hausen...

According to the latest statistics of Yaozhi Data, in May 2021, CDE has undertaken a total of 820 new drug registration applications (except f

June 05, 2021
The policy of the Medical Insurance Bureau is outrageous! A large number of drugs such as Pfizer, AZ, and Harbin Pharmaceuticals have been removed from the Internet

On December 25, 2020, the Office of the National Medical Security Administration issued the "Notice on Accelerating the Implementation of the Pharmaceutical Price and Recruitment Credit Evaluation Sys

June 04, 2021
Qilu, Hengrui, CSPC... 83 varieties have been reviewed! 16 varieties were the first to be reviewed, and a variety of blockbuster injections entered the centralized procurement

According to the consistency evaluation analysis system of Yaozhi Data Enterprise Edition, 74 new consistency evaluation acceptance numbers we

June 03, 2021
"Tumor treatment shady" punishment result is here! Where will cell therapy go?

On May 28, the official website of the Supervision Office of the Shanghai Municipal Health Commission announced the relevant punishment result

June 02, 2021
Nature: reactivating the paralyzed immune system to attack fatal brain cancer

Glioma is the most common primary central nervous system tumor. Because it has no obvious boundary with normal brain tissue, it is difficult t

June 01, 2021
New double-anti-ADC and ADC players enter the game, and financing companies "challenge" leading position in May

According to incomplete statistics, as of May 31, 54 financing incidents (excluding IPOs, mergers and acquisitions, equity financing, private

May 31, 2021
Innovative drugs, vaccines, CDMO, and the IPOs of major new players in the pharmaceutical industry this Wednesday, who is more powerful?

"Innovation", as the main driving force of the biomedical industry in recent years, has forced the industry to actively seek technological and

May 28, 2021
Hu Yunfu: Strategies and Trends of Drug Clinical Companion Diagnosis in New Drug Development

In the past few years, the proportion of targeted drugs in the new drug projects approved by the US FDA has gradually increased, from the comm

May 27, 2021
Heavy! The world's first phase III clinical data of the new crown inactivated vaccine is officially released

On May 26, the international medical journal "The Journal of the American Medical Association" (The Journal of the American Medical Associatio

May 26, 2021
Domestically-made innovative collectives go to sea, and clinical data of a number of blockbuster studies have been announced! Hengrui, Hausen...

一. Overview The ASCO annual meeting is known as the "Oscar Ceremony" of international oncology, and the research that is selected for the Oral Abstract Session every year is particula

May 20, 2021
Check out over 100 antibody drugs approved by the FDA! Double antibody, ADC...Where is the new flashpoint?

Since the US FDA approved the first monoclonal antibody OKT3 (muromonab-CD3) in 1986, it has a history of 35 years. Today, antibody drugs acco

May 18, 2021
60 billion market size! The fifth batch of centralized procurement of large varieties and leading companies gathered; Pfizer, AstraZeneca, Hengrui, Kelun, Chia Tai Tianqing...

Recently, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on the Implementation of the Fifth Batch of National-Organize

May 17, 2021
This pharmaceutical field ushered in a R&D boom

On May 7, Eimerizumab was approved for the second indication-routine preventive treatment for adults and children with hemophilia A without in

May 13, 2021
The transformation of Chinese medicine companies: 8 companies have revenues of over 10 billion yuan, and 23 companies have invested more than 100 million yuan in R&D

Among the six major pharmaceutical segments in the A-share market, traditional Chinese medicine and pharmaceutical business (pharmaceutical circulation) have been at the lowest valuations for many yea

May 11, 2021
Heavy! Sinopharm Zhongsheng New Crown Vaccine Obtained Emergency Use Authorization by WHO

On May 7, the Director-General of the World Health Organization (WHO) Tan Desai announced that the new coronavirus inactivated vaccine (Vero c

May 09, 2021
In 2025, global medical expenditures will reach US$1.6 trillion, and 20 therapeutic areas will increase at a rate of growth rate, including immunology, oncology, neurology...

Recently, according to the latest report of the IQVIA Institute of Human Data Science, "Outlook 2025: Global Medical Expenditure and Use Trend

May 08, 2021
The world's top 20 best-selling drugs are released! Roche's three major monoclonal antibodies fell, O drugs fell behind; macromolecular drugs accounted for half of the country...

Recently, according to Evaluate Pharma data, the Fierce Pharma website released a list of the world’s top 20 drug sales. AbbVie’s Hummer, Merck’s Kerida and Bristol-Myers Squibb’s Rui Fumei ar

May 07, 2021
Pfizer BCMA×CD3 double-antibody suspension patients are enrolled. How safe is the double-antibody drug?

On May 4, Pfizer announced its 2021Q1 results. The company's revenue in the first quarter reached US$14.6 billion, an increase of 42% year-on-year. The main driver of the performance was the new crown

May 06, 2021
Revenue ranking in the CDMO field in 2020, the market share of WuXi Biologics will fall within five years

Nowadays, foreign multinational pharmaceutical companies have divested their production functions and advocated asset-light operations, which has brought about an increase in the overall outsour

April 30, 2021
If you want to make a breakthrough in the PD-1 market under the trend of low prices, Fosun has only this set of "seven injuries"!

On April 22, Henlius's "Slulimumab injection (ie, recombinant anti-PD-1 humanized monoclonal antibody injection)" was used for unresectable or highly metastatically unresectable or highly metastatic a

Casa

Product

Whatsapp

Sobre nós

Inquérito

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

enviar